{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:36:19Z","timestamp":1779309379993,"version":"3.51.4"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea Research Foundation for Gynecologic Cancer","award":["2024-1"],"award-info":[{"award-number":["2024-1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Osteoporosis is a major public health concern, due to its high risk of fractures and disability and associated medical costs. Romosozumab, an anabolic agent, has been approved for the treatment of osteoporosis in postmenopausal women at high risk of fractures. However, limited data exist on its long-term effects in the Korean population, particularly regarding its impact on bone mineral density (BMD), bone turnover markers, and body composition. This study aimed to evaluate the 12-month effects of romosozumab treatment on BMD, bone turnover markers, and body composition in postmenopausal Korean women with high-fracture-risk osteoporosis (T-scores \u2264 \u22123.0). Additionally, the impact of concomitant postmenopausal hormone therapy (MHT) on BMD changes was assessed. Methods: This multicenter, retrospective observational study included 50 postmenopausal women diagnosed with osteoporosis (T-scores \u2264 \u22123.0) who received 12 monthly doses of romosozumab (210 mg) at two hospitals in Korea. Changes in BMD in the lumbar spine, femoral neck, and total hip were assessed using dual-energy X-ray absorptiometry (DXA). Bone turnover markers, including procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide of type 1 collagen (CTX), were measured at baseline and at 3, 6, and 12 months. Changes in body composition, including the skeletal muscle index (SMI), body mass index (BMI), and visceral adipose tissue (VAT), were also analyzed. Results: After 12 months of romosozumab treatment, BMD significantly increased at the lumbar spine (14.65%), femoral neck (6.58%), and total hip (4.19%) (p &lt; 0.05). P1NP levels increased significantly at 3 months (+37.9%), but returned to baseline at 6 months, while CTX levels continuously decreased (\u221227.8%) over 12 months. No significant changes were observed in SMI or BMI, but the VAT showed a slight decreasing trend (p &lt; 0.05). Additionally, patients receiving concomitant MHT demonstrated a significantly greater increase in lumbar spine BMD compared to those receiving romosozumab alone (p &lt; 0.05), while no significant differences were observed in femoral neck and total hip BMD. Conclusions: This study demonstrated that 12 months of romosozumab treatment significantly improved BMD and bone turnover markers in postmenopausal Korean women with severe osteoporosis. The combination of romosozumab and MHT further enhanced lumbar spine BMD gains. These findings support the use of romosozumab as an effective treatment for high-risk osteoporotic fractures in postmenopausal Korean women, and suggest potential benefits of a combined therapeutic approach.<\/jats:p>","DOI":"10.3390\/jcm14092958","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:44:52Z","timestamp":1745495092000},"page":"2958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy"],"prefix":"10.3390","volume":"14","author":[{"given":"Jung Yoon","family":"Park","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Moo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Menopause Clinic Grace Women\u2019s Hospital, Goyang 10447, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-7243","authenticated-orcid":false,"given":"Jae-Yen","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Jin","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Menopause Clinic Grace Women\u2019s Hospital, Goyang 10447, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mee-Ran","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn-Jee","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"ref_1","first-page":"83","article-title":"Epidemiology and economic burden of osteoporosis in Greece","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"ref_2","unstructured":"(2024, August 08). 10 Rules for Preventing and Managing Osteoporosis. Korea Disease Control and Prevention Agency. Available online: https:\/\/www.kdca.go.kr\/board\/board.es?mid=a20501010000&bid=0015&act=view&list_no=723657."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.11005\/jbm.2020.27.4.281","article-title":"Osteoporosis and osteoporotic fracture fact sheet in Korea","volume":"27","author":"Ahn","year":"2020","journal-title":"J. Bone Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.11005\/jbm.2013.20.1.17","article-title":"National healthcare budget impact analysis of the treatment for osteoporosis and fractures in Korea","volume":"20","author":"Yi","year":"2013","journal-title":"J. Bone Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","author":"WA","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: Meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jbmr.1673","article-title":"Bone strength and surrogate markers: The first, second, and third fiddle","volume":"27","author":"Miller","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","article-title":"Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: An update on SABRE","volume":"12","author":"Black","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","journal-title":"Bone"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2040622310374783","article-title":"Bisphosphonates for the treatment of osteoporosis: Insights for clinicians","volume":"1","author":"Lewiecki","year":"2010","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"1","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3803\/EnM.2020.848","article-title":"Romosozumab in postmenopausal Korean women with osteoporosis: A randomized, double-blind, placebo-controlled efficacy and safety study","volume":"36","author":"Baek","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2025, January 14). FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk of Fracture. 9 April 2019, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture."},{"key":"ref_20","unstructured":"Ministry of Food and Drug Safety (2025, January 14). Romosozumab Approval and Drug Information, Available online: https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=201903599aupdateTs2025-01-12%2015:53:12.0b."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_23","unstructured":"(2024, July 24). IMPORTANT SAFETY INFORMATION FOR EVENITY\u00ae. Available online: https:\/\/www.evenityproliahcp.com\/starting-evenity\/dosing."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/2958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:21:03Z","timestamp":1760030463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/2958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14092958"],"URL":"https:\/\/doi.org\/10.3390\/jcm14092958","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}